Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 13/20 | 0.48 |
| ▸ | FEN1 | P39748 | 13/20 | 0.48 |
| ▸ | ERCC4 | Q92889 | 13/20 | 0.48 |
| ▸ | DNASE1 | P24855 | 3/20 | 0.46 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5122141 | 0.75 | SMN1; SMN2 (0.48) | ERCC1FEN1ERCC4DNASE1 | |
| SCHEMBL1568170 | 0.66 | L3MBTL1 (0.53) | — | |
| SCHEMBL31659577 | 0.62 | THRB (0.60) | — | |
| SCHEMBL1581077 | 0.62 | PBK (0.66) | PBK | |
| SCHEMBL5123552 | 0.62 | SMN1; SMN2 (0.61) | ERCC1FEN1ERCC4DNASE1 | |
| SCHEMBL22027680 | 0.62 | ERCC1 (0.68) | ERCC1FEN1ERCC4DNASE1 | |
| SCHEMBL2313512 | 0.61 | PBK (0.67) | PBK | |
| SCHEMBL13947082 | 0.61 | SMN1; SMN2 (0.52) | — | |
| SCHEMBL6656091 | 0.61 | ERCC1 (1.00) | ERCC1FEN1ERCC4DNASE1 | |
| SCHEMBL13167386 | 0.60 | NPSR1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150527-B2 | Metalloenzyme inhibitor compounds | INNOCRIN PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140303157-A1 | METALLOENZYME INHIBITOR COMPOUNDS | INNOCRIN PHARMACEUTICALS, INC. | 2014-10-09 | — | — | US | disclosed |
| US-20140303157-A1 | METALLOENZYME INHIBITOR COMPOUNDS | INNOCRIN PHARMACEUTICALS, INC. | 2014-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303157-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | ERCC1 2919/4885FEN1 692/4885ERCC4 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.